DRM02

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rosacea

Conditions

Rosacea

Trial Timeline

Oct 1, 2013 → Mar 1, 2014

About DRM02

DRM02 is a phase 2 stage product being developed by Eli Lilly for Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT01993446. Target conditions include Rosacea.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01993446Phase 2Completed
NCT01993433Phase 2Completed
NCT01993420Phase 2Completed